3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
257
Breast Neoplasms
173
Neoplasms
170
Colorectal Neoplasms
156
Neoplasm Metastasis
127
Melanoma
120
Recurrence
118
Prostatic Neoplasms
118
Leukemia, Myeloid, Acute
117
Pancreatic Neoplasms
116
Ovarian Neoplasms
112
Multiple Myeloma
104
Lung Neoplasms
96
Stomach Neoplasms
92
Squamous Cell Carcinoma of Head and Neck
86
Triple Negative Breast Neoplasms
85
Glioblastoma
82
Lymphoma
77
Lymphoma, Non-Hodgkin
75
Lymphoma, Large B-Cell, Diffuse
65
Precursor Cell Lymphoblastic Leukemia-Lymphoma
64
Carcinoma, Renal Cell
64
Advanced Solid Tumor
59
Endometrial Neoplasms
58
Carcinoma, Hepatocellular
58
Small Cell Lung Carcinoma
55
Uterine Cervical Neoplasms
53
Sarcoma
53
Myelodysplastic Syndromes
51
Leukemia
50
Interventions
ON 01910
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Epidermolysis Bullosa Dystrophica
×
1 year
×
Clear all
NCT03786237
2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2
Completed
2 enrolled